| Browse |
| Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants. |
| Lineage (WHO label)   | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |
|---|---|---|---|---|---|---|---|---|---|---|
| JC.1 | N | US-CDC-N-3 | GGGAGCCTTGAATACACCAAAA | 22 | 45.45 | 28681 | 28702 | F | -22824.1 | US |
| JC.1 | N | US-CDC-N-3 | TGTAGCACGATTGCAGCATTG | 21 | 47.62 | 28752 | 28732 | R | -23779.6 | US |
| JC.1 | N | SC2 | CTGCAGATTTGGATGATTTCTCC | 23 | 43.48 | 29463 | 29485 | F | -23117.2 | US |
| JC.1 | N | SC2 | CCTTGTGTGGTCTGCATGAGTTTAG | 25 | 48 | 29554 | 29530 | R | -26482.3 | US |
| B.1.334 | N | US-CDC-N-1 | GACCCCAAAATCAGCGAAAT | 20 | 45 | 28287 | 28306 | F | -20656.7 | US |
| B.1.334 | N | US-CDC-N-1 | TCTGGTTACTGCCAGTTGAATCTG | 24 | 45.83 | 28358 | 28335 | R | -25148.4 | US |
| B.1.334 | N | US-CDC-N-2 | TTACAAACATTGGCCGCAAA | 20 | 40 | 29164 | 29183 | F | -21115.5 | US |
| B.1.334 | N | US-CDC-N-2 | GCGCGACATTCCGAAGAA | 18 | 55.56 | 29230 | 29213 | R | -21404.2 | US |
| B.1.334 | N | US-CDC-N-3 | GGGAGCCTTGAATACACCAAAA | 22 | 45.45 | 28681 | 28702 | F | -22824.1 | US |
| B.1.334 | N | US-CDC-N-3 | TGTAGCACGATTGCAGCATTG | 21 | 47.62 | 28752 | 28732 | R | -23779.6 | US |
| B.1.334 | N | SC2 | CTGCAGATTTGGATGATTTCTCC | 23 | 43.48 | 29463 | 29485 | F | -23117.2 | US |
| B.1.334 | N | SC2 | CCTTGTGTGGTCTGCATGAGTTTAG | 25 | 48 | 29554 | 29530 | R | -26482.3 | US |
| Lineage (WHO label) | Target Gene | Primer Name | Primer Sequence | Primer Length | Primer GC Content (%) | Start Position | End Position | Primer Direction | ΔG (cal) | Primer first used |